pimobendan has been researched along with Chronic Disease in 14 studies
pimobendan: produces arterial & venous dilatation in dogs; structure given in first source
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The long-term beneficial effects of pimobendan in the treatment of chronic heart failure (CHF) have not been established, so the present trial compared pimobendan (1." | 9.10 | Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: the effects of pimobendan on chronic heart failure study (EPOCH study). ( , 2002) |
| "317 patients with stable symptomatic heart failure, objectively impaired exercise capacity, and an ejection fraction of 45% or lower who were treated with at least an angiotensin converting enzyme inhibitor and a diuretic and who tolerated a test dose of pimobendan." | 9.08 | Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial. ( Dumont, JM; Heinrich-Nols, J; Hjalmarsson, AC; Just, H; La Framboise, D; Lubsen, J; Remme, WJ; Seed, P, 1996) |
| "The long-term efficacy of the positive inotropic and vasodilator drug, pimobendan, was assessed in 21 patients suffering from symptomatic heart failure." | 9.07 | Clinical effects of long-term administration of pimobendan in patients with moderate congestive heart failure. ( Asanoi, H; Ejiri, M; Horikoshi, I; Kihara, Y; Sasayama, S; Terada, Y; Yokawa, S; Yoshida, S, 1994) |
| "The acute systemic hemodynamic effects of the calcium antagonist nisoldipine and the pyridazinone-derivative pimobendan, a phosphodiesterase inhibitor with vasodilating as well as positive inotropic properties, were studied in conscious pigs with chronic heart failure." | 7.67 | Acute hemodynamic effects of nisoldipine and pimobendan in conscious pigs with chronic heart failure. ( Duncker, DJ; Roelandt, JR; van der Giessen, WJ; van Woerkens, LJ; Verdouw, PD, 1989) |
| "Pimobendan is a positive inotropic agent that dilates blood vessels and sensitizes the myocardium to calcium." | 6.68 | [Effects of pimobendan on pulmonary hypertension in patients with chronic pulmonary emphysema]. ( Fujikane, T; Matsumoto, H; Sasaki, N; Shimizu, T; Takahashi, M; Takahashi, T; Takeda, A; Tsuji, T; Yamazaki, Y, 1997) |
| "Pimobendan is a positive inotropic agent with additional calcium-sensitizing effects of the phosphodiesterase III-inhibitor group." | 6.67 | [Pimobendan (UDCG 115 BS) in long-term therapy of chronic heart failure]. ( Bergler-Klein, J; Globits, S; Glogar, D; Mayr, H; Porenta, G; Sochor, H; Stefenelli, T, 1992) |
| "The long-term beneficial effects of pimobendan in the treatment of chronic heart failure (CHF) have not been established, so the present trial compared pimobendan (1." | 5.10 | Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: the effects of pimobendan on chronic heart failure study (EPOCH study). ( , 2002) |
| "317 patients with stable symptomatic heart failure, objectively impaired exercise capacity, and an ejection fraction of 45% or lower who were treated with at least an angiotensin converting enzyme inhibitor and a diuretic and who tolerated a test dose of pimobendan." | 5.08 | Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial. ( Dumont, JM; Heinrich-Nols, J; Hjalmarsson, AC; Just, H; La Framboise, D; Lubsen, J; Remme, WJ; Seed, P, 1996) |
| "The long-term efficacy of the positive inotropic and vasodilator drug, pimobendan, was assessed in 21 patients suffering from symptomatic heart failure." | 5.07 | Clinical effects of long-term administration of pimobendan in patients with moderate congestive heart failure. ( Asanoi, H; Ejiri, M; Horikoshi, I; Kihara, Y; Sasayama, S; Terada, Y; Yokawa, S; Yoshida, S, 1994) |
| "The acute systemic hemodynamic effects of the calcium antagonist nisoldipine and the pyridazinone-derivative pimobendan, a phosphodiesterase inhibitor with vasodilating as well as positive inotropic properties, were studied in conscious pigs with chronic heart failure." | 3.67 | Acute hemodynamic effects of nisoldipine and pimobendan in conscious pigs with chronic heart failure. ( Duncker, DJ; Roelandt, JR; van der Giessen, WJ; van Woerkens, LJ; Verdouw, PD, 1989) |
| "Pimobendan is a positive inotropic agent that dilates blood vessels and sensitizes the myocardium to calcium." | 2.68 | [Effects of pimobendan on pulmonary hypertension in patients with chronic pulmonary emphysema]. ( Fujikane, T; Matsumoto, H; Sasaki, N; Shimizu, T; Takahashi, M; Takahashi, T; Takeda, A; Tsuji, T; Yamazaki, Y, 1997) |
| "Pimobendan is a positive inotropic agent with additional calcium-sensitizing effects of the phosphodiesterase III-inhibitor group." | 2.67 | [Pimobendan (UDCG 115 BS) in long-term therapy of chronic heart failure]. ( Bergler-Klein, J; Globits, S; Glogar, D; Mayr, H; Porenta, G; Sochor, H; Stefenelli, T, 1992) |
| "Pimobendan is a drug with positive inotropic effects that additionally inhibits the production of proinflammatory cytokines." | 2.42 | The role of Ca++-sensitizers for the treatment of heart failure. ( Boldt, J; Kirchner, J; Lehmann, A, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (21.43) | 18.7374 |
| 1990's | 6 (42.86) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 1 (7.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Murai, K | 1 |
| Seino, Y | 1 |
| Kimata, N | 1 |
| Inami, T | 1 |
| Murakami, D | 1 |
| Abe, J | 1 |
| Yodogawa, K | 1 |
| Maruyama, M | 1 |
| Takano, M | 1 |
| Ohba, T | 1 |
| Ibuki, C | 1 |
| Mizuno, K | 1 |
| Kohno, M | 1 |
| Lehmann, A | 1 |
| Boldt, J | 1 |
| Kirchner, J | 1 |
| Sasayama, S | 1 |
| Asanoi, H | 2 |
| Kihara, Y | 1 |
| Yokawa, S | 1 |
| Terada, Y | 1 |
| Yoshida, S | 1 |
| Ejiri, M | 1 |
| Horikoshi, I | 1 |
| Inoue, H | 1 |
| Lubsen, J | 1 |
| Just, H | 1 |
| Hjalmarsson, AC | 1 |
| La Framboise, D | 1 |
| Remme, WJ | 1 |
| Heinrich-Nols, J | 1 |
| Dumont, JM | 1 |
| Seed, P | 1 |
| Yamazaki, Y | 1 |
| Matsumoto, H | 1 |
| Takeda, A | 1 |
| Takahashi, T | 1 |
| Sasaki, N | 1 |
| Takahashi, M | 1 |
| Tsuji, T | 1 |
| Fujikane, T | 1 |
| Shimizu, T | 1 |
| Duncker, DJ | 2 |
| Haitsma, DB | 1 |
| Liem, DA | 1 |
| Heins, N | 1 |
| Stubenitsky, R | 1 |
| Verdouw, PD | 2 |
| Bergler-Klein, J | 1 |
| Globits, S | 1 |
| Stefenelli, T | 1 |
| Mayr, H | 1 |
| Porenta, G | 1 |
| Sochor, H | 1 |
| Glogar, D | 1 |
| Katz, SD | 1 |
| Kubo, SH | 1 |
| Jessup, M | 1 |
| Brozena, S | 1 |
| Troha, JM | 1 |
| Wahl, J | 1 |
| Cohn, JN | 1 |
| Sonnenblick, EH | 1 |
| LeJemtel, TH | 1 |
| van der Giessen, WJ | 1 |
| van Woerkens, LJ | 1 |
| Roelandt, JR | 1 |
| Baumann, G | 1 |
| Ningel, K | 1 |
| Permanetter, B | 1 |
| Hauf, GF | 1 |
| Grom, E | 1 |
| Jähnchen, E | 1 |
| Roskamm, H | 1 |
2 reviews available for pimobendan and Chronic Disease
| Article | Year |
|---|---|
[Pharmacological treatment of heart failure].
Topics: Acute Disease; Adrenergic beta-Antagonists; Amiodarone; Angiotensin Receptor Antagonists; Angiotensi | 2003 |
The role of Ca++-sensitizers for the treatment of heart failure.
Topics: Calcium; Cardiotonic Agents; Chronic Disease; Clinical Trials as Topic; Dobutamine; Heart Failure; H | 2003 |
8 trials available for pimobendan and Chronic Disease
| Article | Year |
|---|---|
Clinical effects of long-term administration of pimobendan in patients with moderate congestive heart failure.
Topics: Activities of Daily Living; Cardiotonic Agents; Chronic Disease; Dose-Response Relationship, Drug; D | 1994 |
Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial.
Topics: Aged; Cardiotonic Agents; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Exerci | 1996 |
[Effects of pimobendan on pulmonary hypertension in patients with chronic pulmonary emphysema].
Topics: Aged; Blood Pressure; Cardiac Output; Chronic Disease; Humans; Hypertension, Pulmonary; Male; Middle | 1997 |
Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: the effects of pimobendan on chronic heart failure study (EPOCH study).
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Cardiotonic Agents | 2002 |
[Pimobendan (UDCG 115 BS) in long-term therapy of chronic heart failure].
Topics: Cardiac Volume; Cardiotonic Agents; Chronic Disease; Double-Blind Method; Echocardiography; Electroc | 1992 |
A multicenter, randomized, double-blind, placebo-controlled trial of pimobendan, a new cardiotonic and vasodilator agent, in patients with severe congestive heart failure.
Topics: Cardiotonic Agents; Chronic Disease; Double-Blind Method; Exercise Test; Female; Heart Failure; Hemo | 1992 |
Clinical efficacy of pimobendan (UD-CG 115 BS) in patients with chronic congestive heart failure.
Topics: Adult; Blood Pressure; Cardiac Output; Cardiomyopathy, Dilated; Cardiotonic Agents; Chronic Disease; | 1989 |
Acute and long-term hemodynamic effects of pimobendan (UD-CG 115 BS) in comparison with captopril.
Topics: Adult; Captopril; Cardiotonic Agents; Chronic Disease; Exercise; Female; Heart Failure; Heart Rate; | 1989 |
4 other studies available for pimobendan and Chronic Disease
| Article | Year |
|---|---|
Efficacy and limitations of oral inotropic agents for the treatment of chronic heart failure.
Topics: Administration, Oral; Aged; Aged, 80 and over; Cardiotonic Agents; Chronic Disease; Cross-Sectional | 2013 |
Positive inotropic agents: a double-edged sword for chronic heart failure.
Topics: Cardiotonic Agents; Chronic Disease; Clinical Trials as Topic; Dose-Response Relationship, Drug; Hea | 1996 |
Beneficial effects of the Ca2+ sensitizer EMD 57033 in exercising pigs with infarction-induced chronic left ventricular dysfunction.
Topics: Animals; Calcium; Cardiotonic Agents; Chronic Disease; Exercise Test; Female; Hemodynamics; Male; My | 2001 |
Acute hemodynamic effects of nisoldipine and pimobendan in conscious pigs with chronic heart failure.
Topics: Acid-Base Equilibrium; Animals; Blood Gas Analysis; Chronic Disease; Heart Failure; Hemodynamics; Ni | 1989 |